The medication baricitinib is showing positive results for helping rheumatoid arthritis patients, even in those who aren’t responding to other treatments.
A new drug reduced the number of affected joints in patients with refractory rheumatoid arthritis that has lessening or no response to other treatments, according to an international clinical trial.
The drug, baricitinib, reduced the number of affected joints in about half the study’s participants, offering a potential treatment for people with few options to ease the progressive condition.
Rheumatoid arthritis affects 1.5 percent of people in developed countries, causing pain stiffness, swelling and the destruction of small joints, such as in the hands and feet.
Although drugs have been effective in blocking immune mechanisms to reduce inflammation, many patients find the drugs lose their efficacy, carry significant side effects or both.
Regardless of participants’ previous medical history or drug treatments, researchers said baricitinib helped their conditions.
“The drug worked well across all patient subgroups, independently of what they’d been taking before or how long they’d had the disease,” Dr. Mark Genovese, a professor of immunology and rheumatology at Stanford University, said in a press release.
For the study, published in the New England Journal of Medicine, researchers recruited 527 patients in 24 countries who had rheumatoid arthritis for an average of 14 years, treating them with a 4-milligram dose of baricitinib, 2-milligram dose of baricitinib or placebo.
|Read Full Article: New drug baricitinib effective for refractory rheumatoid arthritis – UPI.com|